Canada - English - Health Canada

bayer inc - iopromide - solution - 77% - iopromide 77% - roentgenography

Singapore - English - HSA (Health Sciences Authority)

bayer (south east asia) pte ltd - iopromide eqv iodine - injection - 623.40 mg - iopromide eqv iodine 300 mg/ml

Singapore - English - HSA (Health Sciences Authority)

bayer (south east asia) pte ltd - iopromide eqv iodine - injection - 768.86 mg - iopromide eqv iodine 370 mg/ml

Kenya - English - Pharmacy and Poisons Board

bayer pharma ag bayer pharma ag 13342 berlin germany - iopromide - solution for injection/infusion - 1 ml contains 623 mg iopromide (equivalent to 300… - contrast media - non-iodinated x-ray contrast

Kenya - English - Pharmacy and Poisons Board

bayer pharma ag bayer pharma ag 13353 berlin germany - iopromide - solution for injection/infusion - 1 ml contains 769 mg iopromide (equivalent to 370… - contrast media - iodinated x-raycontrast media:

United States - English - NLM (National Library of Medicine)

bayer healthcare pharmaceuticals inc. - iopromide (unii: 712bac33mz) (iopromide - unii:712bac33mz) - ultravist® injection is an iodinated contrast agent indicated in adults pediatric patients for use only with an automated contrast injection system, contrast management system, or contrast media transfer set approved or cleared for use with this contrast agent in this imaging bulk package. risk summary there are no data on ultravist injection use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. iopromide crosses the placenta and reaches fetal tissues in small amounts (see data). in animal reproduction studies, intravenous administration of iopromide to pregnant rats and rabbits during organogenesis at doses up to 0.35 and 0.7 times, respectively, the maximum recommended human dose based on body surface area resulted in no relevant adverse developmental effects (see data). . the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of

United States - English - NLM (National Library of Medicine)

bayer healthcare pharmaceuticals inc. - iopromide (unii: 712bac33mz) (iopromide - unii:712bac33mz) - ultravist® injection is an iodinated contrast agent indicated for: ultravist is indicated for: ultravist is indicated for: † specific concentrations and presentations of ultravist are recommended for each type of imaging procedure [see dosage and administration ( 2.2, 2.3, 2.4)]. there are no data on ultravist use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. iopromide crosses the placenta and reaches fetal tissues in small amounts (see data) . in animal reproduction studies, intravenous administration of iopromide to pregnant rats and rabbits during organogenesis at doses up to0.35 and 0.7 times, respectively, the maximum recommended human dose based on body surface area resulted in no relevant adverse developmental effects (see data) . the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defects, loss, or other advers

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - iopromide 312 mg/ml equivalent to iodine 150 mg/ml - solution for infusion - 150 mg/ml - active: iopromide 312 mg/ml equivalent to iodine 150 mg/ml excipient: hydrochloric acid sodium calcium edetate trometamol water for injection

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

bayer co. (malaysia) sdn. bhd. - iopromide -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

bayer co. (malaysia) sdn. bhd. - iopromide -